Topics:

Lung Cancer

Lung Cancer

GlaxoSmithKline has stopped a phase III trial of a novel lung cancer immunotherapeutic agent, after determining that it may not be possible to identify which genetic subgroups may benefit from the treatment.

A biomarker and five clinical factors help to predict which patients with nonsmall-cell lung cancer are at high risk for lung inflammation after radiotherapy.

The new ALK inhibitor certinib showed strong antitumor activity in a phase I expansion study of patients with advanced non-small-cell lung cancer (NSCLC).

In a phase I trial, non–small-cell lung cancer (NSCLC) patients with tumors that expressed PD-L1 had significantly better outcomes with MK-3475 therapy compared with patients with PD-L1–negative tumors.

In this interview we discuss the oncogenes driving the development of squamous cell carcinoma of the lung, a type of non-small-cell lung cancer.

Combining both cetuximab and bevacizumab with platinum-based chemotherapy showed strong efficacy in a phase II trial of patients with advanced non-small-cell lung cancer.

Experts offer guidance on use of epidermal growth factor receptor as a treatment target and a biomarker in lung cancer.

Pages

Subscribe to
Please Wait 20 seconds or click here to close